Strategic Win Through Acquisition of a Bankrupt Asset and a Pivotal Shift

Amylyx Pharmaceuticals (AMLX) acquired atexitide from Eiger BioPharmaceuticals for a mere $35.1 million in July 2024, shortly before Eiger filed for bankruptcy. This decision was made as Amylyx faced a crisis due to the clinical failure and market withdrawal of Relyvrio, its ALS treatment, and aimed to rapidly pivot its portfolio towards the metabolic disease area. The success of this Phase 3 trial demonstrates the value of acquiring undervalued assets and serves as a prime example of successful business development (BD), quickly restoring the company's pipeline competitiveness.

Demonstrates Clinical Efficacy for Post-Bariatric Surgery Hypoglycemia Patients

In the Phase 3 LUCIDITY trial, atexitide showed significant efficacy in patients with moderate-to-severe hyperinsulinemic hypoglycemia (HIH), specifically post-bariatric hypoglycemia (PBH), following bariatric surgery. PBH, which can cause syncope, seizures, and coma by depleting glucose reaching the brain in obese patients, is a serious complication with a high unmet need as there is currently no standard of care (SOC). The clinical results showed that the atexitide group significantly reduced the incidence of severe and serious hypoglycemic events by 55% compared to the placebo group, meeting the primary endpoint. Furthermore, most adverse reactions were mild or moderate, and no specific adverse effects were observed other than injection site pain or diarrhea, ensuring a high safety profile.

Market Value of a Differentiated Mechanism as a GLP-1 Receptor Antagonist

Atexitide operates with a mechanism opposite to that of GLP-1 receptor agonists, such as Zepbound (Eli Lilly, LLY) and Wegovy (Novo Nordisk, NVO), which currently dominate the obesity and diabetes markets. This drug is based on exendin (9-39), a GLP-1 receptor antagonist, which competitively blocks the receptor and inhibits excessive insulin secretion, thereby stabilizing blood sugar levels. This mechanism, which creates a niche market in the face of the rapid growth of agonists, can provide an optimal treatment alternative for patients with failed blood sugar control after bariatric surgery. In particular, with the increasing number of metabolic surgery patients in modern society, this unique approach is expected to establish a basis for Amylyx to build its own exclusive territory.

Regulatory Support and Plans for Approval Application This Year

The U.S. Food and Drug Administration (FDA) has already supported the rapid development of atexitide by granting Breakthrough Therapy Designation for PBH and congenital hyperinsulinism. It has also secured Orphan Drug Designation for rare hyperinsulinemic hypoglycemia, which will guarantee tax benefits and exclusive marketing rights upon approval. Amylyx plans to submit a New Drug Application (NDA) to the FDA by the end of 2026, and given the urgency of the unmet medical need, a rapid review is expected. With these approval milestones becoming visible, Amylyx has the opportunity to overcome the significant reputational damage caused by the discontinuation of its ALS treatment and re-emerge as a true metabolic disease biotech.